Structural studies of the human α1 glycine receptor via site-specific chemical cross-linking coupled with mass spectrometry
Biophysical Reports · 2024
DOI: 10.1016/j.bpr.2024.100184 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biophysical Reports, 2024. Verfasst von Rathna J Veeramachaneni und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Biochemistry, Duquesne University Pittsburgh, Pittsburgh, Pennsylvania. Hauptthemen laut MEDLINE: Receptors, Glycine, Cross-Linking Reagents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIMH NIH HHS, National Institute of Health, Pennsylvania Department of Health.
Abstract (Originalsprache)
By identifying distance constraints, chemical cross-linking coupled with mass spectrometry (CX-MS) can be a powerful complementary technique to other structural methods by interrogating macromolecular protein complexes under native-like conditions. In this study, we developed a CX-MS approach to identify the sites of chemical cross-linking from a single targeted location within the human α1 glycine receptor (α1 GlyR) in its apo state. The human α1 GlyR belongs to the family of pentameric ligand-gated ion channel receptors that function in fast neurotransmission. A single chemically reactive cysteine was reintroduced into a Cys null α1 GlyR construct at position 41 within the extracellular domain of human α1 homomeric GlyR overexpressed in a baculoviral system. After purification and reconstitution into vesicles, methanethiosulfonate-benzophenone-alkyne, a heterotrifunctional cross-linker, was site specifically attached to Cys41 via disulfide bond formation. The resting receptor was then subjected to UV photocross-linking. Afterward, monomeric and oligomeric α1 GlyR bands from SDS-PAGE gels were trypsinized and analyzed by tandem MS in bottom-up studies. Dozens of intrasubunit and intersubunit sites of α1 GlyR cross-linking were differentiated and identified from single gel bands of purified protein, showing the utility of this experimental approach to identify a diverse array of distance constraints of the α1 GlyR in its resting state. These studies highlight CX-MS as an experimental approach to identify chemical cross-links within full-length integral membrane protein assemblies in a native-like lipid environment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemistry and Biochemistry, Duquesne University Pittsburgh, Pittsburgh, Pennsylvania.
- Department of Chemistry and Biochemistry, Duquesne University Pittsburgh, Pittsburgh, Pennsylvania; Department of Chemistry, Ohio Wesleyan University, Delaware, Ohio.
- Graduate School of Pharmaceutical Sciences, Duquesne University Pittsburgh, Pittsburgh, Pennsylvania.
- Department of Chemistry and Biochemistry, Duquesne University Pittsburgh, Pittsburgh, Pennsylvania. Electronic address: casciom@duq.edu.
Förderung
- NIMH NIH HHS
- National Institute of Health
- Pennsylvania Department of Health
- National Science Foundation
Zitieren
APA
Veeramachaneni, R. J., Donelan, C. A., Tomcho, K. A., Aggarwal, S., Lapinsky, D. J., & Cascio, M. (2024). Structural studies of the human α1 glycine receptor via site-specific chemical cross-linking coupled with mass spectrometry. Biophysical Reports. https://doi.org/10.1016/j.bpr.2024.100184
Vancouver
Veeramachaneni RJ, Donelan CA, Tomcho KA, Aggarwal S, Lapinsky DJ, Cascio M. Structural studies of the human α1 glycine receptor via site-specific chemical cross-linking coupled with mass spectrometry. Biophysical Reports. 2024. doi:10.1016/j.bpr.2024.100184
BibTeX
@article{Veeramachaneni2024,
author = {Veeramachaneni, Rathna J and Donelan, Chelsee A and Tomcho, Kayce A and Aggarwal, Shaili and Lapinsky, David J and Cascio, Michael},
title = {Structural studies of the human α1 glycine receptor via site-specific chemical cross-linking coupled with mass spectrometry},
journal = {Biophysical Reports},
year = {2024},
doi = {10.1016/j.bpr.2024.100184}
}
EUVIMED